VPC
RGNX icon

Vestal Point Capital’s Regenxbio RGNX Stock Holding History

Vestal Point Capital’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$909K Buy
108,525
+74,525
+219% +$783K 0.03% 86
2025
Q4 		$490K Buy
+34,000
New +$424K 0.02% 75

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vestal Point Capital's RGNX Position: Q1 2026 in Review

Vestal Point Capital increased its Regenxbio (RGNX) stake by 219% in Q1 2026, buying an estimated $783K and bringing the position to 108,525 shares worth $909K. The position accounts for 0.03% of the portfolio, ranked #86.

Vestal Point Capital first reported a position in RGNX in Q4 2025 and has held it in 2 quarters since. 178 funds tracked by Wall St. Rank hold RGNX as of Q1 2026.

  • Vestal Point Capital held 108,525 shares of Regenxbio worth $909K as of Q1 2026.
  • Vestal Point Capital bought 74,525 Regenxbio shares in Q1 2026, an estimated $783K.
  • Regenxbio made up 0.03% of Vestal Point Capital's portfolio in Q1 2026, its #86 holding.
  • Vestal Point Capital first reported a position in Regenxbio in Q4 2025 and has held it in 2 quarters since.
  • 178 funds tracked by Wall St. Rank held Regenxbio as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.